Bristol-Myers Squibb CompanyBMY

• Phase 2Zola-cel 자가면역 혈구감소증 세포치료 임상시작 전Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)
  62%
• Phase 3조현병 치료제 KarXT 재발 방지 유효성 평가 임상시작 전Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
  31%
• Phase ?조현병 신약 KarXT 구토방지제 병용 안전성 평가시작 전Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers
  39%
• Phase 1BMS-986517 진행성 고형암 1/2a상 임상모집 중A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
  72%
• Phase 2위암·식도암 1차 치료 푸미타믹 병용 효과 비교 임상모집 중A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
  68%
• Phase 1푸미타믹 진행성 간암 1차 치료 단독 및 병용 임상모집 중A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
  76%
• Phase 3수술 불가 비소세포폐암 대상 푸미타믹 방사선 후속 치료 임상모집 중A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
  56%
• Phase 1나블리메토스타트 알약 제형 1상 임상모집 중A Phase 1 Study of Navlimetostat Tablet Formulations
  73%
• Phase 3퓨미타믹 비소세포폐암 1차 치료 효과 비교 임상모집 중A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
  68%
• Phase 3KarXT 급성기 조현병 치료 유효성·안전성 임상모집 중A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
  31%
• Phase 1Pumitamig 진행성 신장암 단독 및 병용 치료 임상모집 중A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
  72%
• Phase 3재발·불응성 다발골수종 대상 BMS-986393 비교 임상모집 중A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
  73%

성공 확률은 BERA의 AI 모델(임상 설계·약물 구조·과거 사례 기반)이 계산한 값이에요. 실제 결과와 다를 수 있어요.